Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Arbutus Biopharma ( (ABUS) ).
On June 20, 2025, Arbutus Biopharma and Qilu Pharmaceutical mutually agreed to terminate their strategic partnership for the development, manufacturing, and commercialization of imdusiran in Greater China and Taiwan, with all rights reverting to Arbutus. This decision aligns with Qilu’s pipeline reprioritization and Arbutus’ focus on advancing its own pipeline efficiently. Additionally, Arbutus announced the formation of a new Scientific Advisory Board, comprising globally recognized leaders in chronic hepatitis B virus treatment, to guide its strategic evaluation of its cHBV pipeline.
The most recent analyst rating on (ABUS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Arbutus Biopharma stock, see the ABUS Stock Forecast page.
Spark’s Take on ABUS Stock
According to Spark, TipRanks’ AI Analyst, ABUS is a Neutral.
Arbutus Biopharma’s overall stock score is driven by significant financial challenges, with negative profitability and cash flow issues. Technical analysis suggests a neutral short-term outlook, while valuation metrics highlight concerns about overvaluation. Positive developments in HBV treatment are promising but offset by executive turnover and legal uncertainties.
To see Spark’s full report on ABUS stock, click here.
More about Arbutus Biopharma
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is developing imdusiran (AB-729) and an oral PD-1 inhibitor (AB-101) for the treatment of chronic Hepatitis B virus (HBV) infection. Arbutus is also involved in protecting its intellectual property, which is the subject of ongoing lawsuits against Moderna and Pfizer/BioNTech for the use of its patented LNP technology in COVID-19 vaccines.
Average Trading Volume: 942,379
Technical Sentiment Signal: Buy
Current Market Cap: $653.1M
For detailed information about ABUS stock, go to TipRanks’ Stock Analysis page.